Market closed
FRACTYL HEALTH/$GUTS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About FRACTYL HEALTH
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Ticker
$GUTS
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
122
Website
FRACTYL HEALTH Metrics
BasicAdvanced
$106M
Market cap
-
P/E ratio
-$2.16
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$106M
52-week high
$14.50
52-week low
$1.74
Average daily volume
329K
Financial strength
Current ratio
5.577
Quick ratio
5.387
Long term debt to equity
115.28
Total debt to equity
125.057
Management effectiveness
Return on assets (TTM)
-55.32%
Return on equity (TTM)
-286.16%
Valuation
Price to revenue (TTM)
726.285
Price to book
2.11
Price to tangible book (TTM)
2.11
Price to free cash flow (TTM)
-1.159
Growth
Revenue change (TTM)
-14.16%
Earnings per share change (TTM)
-94.80%
3-year earnings per share growth (CAGR)
-56.08%
What the Analysts think about FRACTYL HEALTH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for FRACTYL HEALTH stock.
FRACTYL HEALTH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FRACTYL HEALTH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FRACTYL HEALTH News
AllArticlesVideos
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
GlobeNewsWire·2 days ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
GlobeNewsWire·5 days ago
Fractyl Health to Participate in the Upcoming December Conferences
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for FRACTYL HEALTH stock?
FRACTYL HEALTH (GUTS) has a market cap of $106M as of December 14, 2024.
What is the P/E ratio for FRACTYL HEALTH stock?
The price to earnings (P/E) ratio for FRACTYL HEALTH (GUTS) stock is 0 as of December 14, 2024.
Does FRACTYL HEALTH stock pay dividends?
No, FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next FRACTYL HEALTH dividend payment date?
FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders.
What is the beta indicator for FRACTYL HEALTH?
FRACTYL HEALTH (GUTS) does not currently have a Beta indicator.